Zobrazeno 1 - 10
of 21
pro vyhledávání: '"Rachna Kasliwal"'
Autor:
Megan Clowse, Rebecca Fischer-Betz, Catherine Nelson-Piercy, Angela E. Scheuerle, Brigitte Stephan, Marla Dubinsky, Thomas Kumke, Rachna Kasliwal, Bernard Lauwerys, Frauke Förger
Publikováno v:
Therapeutic Advances in Musculoskeletal Disease, Vol 14 (2022)
Introduction: Chronic inflammatory diseases (CIDs), including rheumatic diseases and other inflammatory conditions, often affect women of reproductive age. Tumor necrosis factor inhibitors (TNFi) are widely used to treat CID, but there is limited inf
Externí odkaz:
https://doaj.org/article/e65b18e6d5e1489cb9a40567081e5652
Autor:
Mitchell S.V. Elkind, Roland Veltkamp, Rachna Kasliwal, Joan Montaner, Jacob Elkins, S. Claiborne Johnston, Kyra Becker, Weihua Tang, Maarten G Lansberg, Aneesh B. Singhal
Publikováno v:
Neurology. 95:e1091-e1104
ObjectiveWe evaluated the effect of 2 doses of natalizumab on functional outcomes in patients with acute ischemic stroke (AIS).MethodsIn this double-blind phase 2b trial, patients with AIS aged 18–80 years with NIH Stroke Scale scores of 5–23 fro
Autor:
Helmut, Butzkueven, Ludwig, Kappos, Heinz, Wiendl, Maria, Trojano, Tim, Spelman, Ih, Chang, Rachna, Kasliwal, Seema, Jaitly, Nolan, Campbell, Pei-Ran, Ho, Stephanie, Licata, François, Ziegler
Publikováno v:
Journal of Neurology, Neurosurgery, and Psychiatry
Journal of neurology, neurosurgery and psychiatry
Journal of neurology, neurosurgery and psychiatry
ObjectiveThe Tysabri Observational Programme (TOP), which began >10 years ago, is an open-label, multinational, prospective observational study evaluating the long-term safety and effectiveness of natalizumab in relapsing-remitting multiple sclerosis
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4c78b9aec3b2708caaa67d13d22053a5
https://opus.bibliothek.uni-augsburg.de/opus4/frontdoor/index/index/docId/93019
https://opus.bibliothek.uni-augsburg.de/opus4/frontdoor/index/index/docId/93019
Autor:
Catherine Nelson-Piercy, Rachna Kasliwal, Angela E. Scheuerle, Marla Dubinsky, Thomas Kumke, Frauke Förger, Brigitte Stephan, Megan E.B. Clowse, Rebecca Fischer-Betz, Bernard Lauwerys
Publikováno v:
American Journal of Gastroenterology. 116:S347-S347
Autor:
Rachna Kasliwal, Cynthia Carrillo-Infante, Fabiana Marinelli, Karen Smirnakis, Tygris investigators, Lily Lee, Patrick Vermersch, Karleyton C. Evans, Michael Hutchinson, John Foley, Martin Stangel, Jonathan Smith, Pei-Ran Ho
Publikováno v:
Multiple sclerosis and related disorders. 39
Background Natalizumab is an effective treatment for multiple sclerosis (MS) and has a well-characterized safety profile, with more than 10 years of postmarketing experience. TYGRIS was a 5-year observational cohort study designed to obtain long-term
Autor:
Rachna Kasliwal, Nolan Campbell, Zheng Ren, Ih Chang, Gary R. Cutter, Lana Zhovtis Ryerson, Evan Riddle, Ryan R. Metzger, John Foley, Judith D. Goldberg, Xiaochun Li, Karen Smirnakis, Pei-Ran Ho, Ilya Kister, Christophe Hotermans
Publikováno v:
Neurology. 93(15)
Objective To use the large dataset from the Tysabri Outreach: Unified Commitment to Health (TOUCH) program to compare progressive multifocal leukoencephalopathy (PML) risk with natalizumab extended interval dosing (EID) vs standard interval dosing (S
Autor:
Ludwig Kappos, Joseph Berger, Heinz Wiendl, Gavin Giovannoni, Ih Chang, Lily Lee, Robert J. Fox, Rachna Kasliwal, Gary Cutter
Publikováno v:
Journal of Neurology, Neurosurgery & Psychiatry. 90:e50.2-e50
IntroductionSince the identification in 2012 of three risk factors for natalizumab-associated progressive multifocal leukoencephalopathy (PML), changes in the PML incidence rate have been of interest.MethodsThe incidence of confirmed PML cases in Bio
Autor:
Rachna Kasliwal, Tim Spelman, Helmut Butzkueven, Xiaoyu Jiang, Maria Trojano, Nolan Campbell, Stephanie Licata, Pei-Ran Ho, Ludwig Kappos, Heinz Wiendl
Publikováno v:
Revue Neurologique. 175:S101-S102
Introduction The TYSABRI Observational Program (TOP) began > 10 years ago to inform on long-term safety and effectiveness of natalizumab in relapsing-remitting multiple sclerosis (RRMS) patients in clinical practice. Objectives Report an interim anal
Autor:
Rachna Kasliwal, Joseph Berger, Robert J. Fox, Gavin Giovannoni, Heinz Wiendl, Ih Chang, Gary Cutter, Lily Lee, Stephanie Licata, Pei-Ran Ho, Ludwig Kappos
Publikováno v:
Revue Neurologique. 175:S96-S97
Introduction Since the 2012 identification of 3 risk factors for natalizumab-associated progressive multifocal leucoencephalopathy (PML) changes in the PML incidence rate have been of interest. Objectives Determine the natalizumab-associated PML inci
Publikováno v:
Drug Safety. 32:499-507
Varenicline tartrate (Champix), a new smoking cessation medicine, was launched in the UK in December 2006. Varenicline is a highly selective partial agonist of the alpha(4)beta(2) nicotinic acetylcholine receptor (alpha(4)beta(2) receptor). The parti